AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Application group (APP) with information via an iPad-based application
Number of subjects: 96
Study 36464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor group (DOC) with augmented physician rounds
Number of subjects: 96
Study 36464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (APP+DOC)
Number of subjects: 96
Study 36464680 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual group (TAU)
Number of subjects: 96
Study 36464680 — intervention group
Group type: EXPERIMENTAL
Intervention: APP+DOC
Number of subjects: 96
Study 36464680 — intervention group
Group type: EXPERIMENTAL
Intervention: DOC
Number of subjects: 96
Study 36464680 — intervention group
Group type: EXPERIMENTAL
Intervention: APP
Number of subjects: 96
Study 36464680 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 96
Study 33331850 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114
Study 33331850 — intervention group
Group type: COMPARATOR
Intervention: Aphakia (contact lens [CL])
Number of subjects: 114
Study 33331850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (IOL and CL)
Number of subjects: 114
Study 33309513 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 14318
Study 33309513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 14318
Study 32381421 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive haemoglobin measurement (SpHb) using Radical-7®
Number of subjects: 43
Study 32381421 — intervention group
Group type: COMPARATOR
Intervention: Laboratory determined haemoglobin (LabHb)
Number of subjects: 43
Study 36418156 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib (25 mg or 75 mg once daily, or 50 mg or 75 mg twice daily)
Number of subjects: 1083
Study 36418156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study 36418156 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 1083
Study 33565558 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium lactis UBBLa-70, n = 10)
Number of subjects: 32
Study 33565558 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic group (Bifidobacterium lactis UBBLa-70 and fructooligosaccharide, n = 11)
Number of subjects: 32
Study 33565558 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, n = 11)
Number of subjects: 32
Study 32592776 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional white-light imaging (WLI) AI system
Number of subjects: 1084
Study 32592776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmagnifying narrow-band imaging (NBI) AI system
Number of subjects: 1084
Study 32592776 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo-carmine dye contrast imaging (Indigo) AI system
Number of subjects: 1084
Study 32592776 — intervention group
Group type: COMPARATOR
Intervention: Comparison of WLI, NBI, and Indigo AI systems
Number of subjects: 1084
Study 35483993 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 21
Study 35483993 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 21
Study 35483993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 21
Study 35483993 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask (VM)
Number of subjects: 21
Study 35483993 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV and CPAP
Number of subjects: 21
Study 33357247 — intervention group
Group type: EXPERIMENTAL
Intervention: SUB dietary guidelines (DG)
Number of subjects: 219
Study 33357247 — intervention group
Group type: EXPERIMENTAL
Intervention: OFF dietary guidelines (DG)
Number of subjects: 219
Study 33357247 — intervention group
Group type: COMPARATOR
Intervention: HAB (habitual diet)
Number of subjects: 219
Study 35896083 — intervention group
Group type: EXPERIMENTAL
Intervention: Relefact LHRH® (100 μg/m2)
Number of subjects: 13
Study 35896083 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13
Study 35896083 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of AEBSF to sampling tubes
Number of subjects: 13
Study 32358357 — intervention group
Group type: COMPARATOR
Intervention: 12 months consolidation period (group A)
Number of subjects: 137
Study 32358357 — intervention group
Group type: COMPARATOR
Intervention: 18 months consolidation period (group B)
Number of subjects: 137
Study 32358357 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HBeAg >1000 S/CO in group B
Number of subjects: 137
Study 32358357 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ALT >133 U/L
Number of subjects: 137
Study 35332737 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive bi-level positive airway pressure (BiPAP) ventilation in treatment group 1
Number of subjects: 155
Study 35332737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy in treatment group 2
Number of subjects: 155
Study 35332737 — intervention group
Group type: COMPARATOR
Intervention: Treatment groups (1 and 2)
Number of subjects: 155
Study 35332737 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 2
Number of subjects: 155
Study 35332737 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 155
Study 35332737 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 155
Study 33602198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using laser diode 940 nm
Number of subjects: 25
Study 33602198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no laser radiation)
Number of subjects: 25
Study 32125257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiscatter grid (ASG) removal
Number of subjects: 53
Study 32125257 — intervention group
Group type: COMPARATOR
Intervention: Antiscatter grid (ASG) present
Number of subjects: 53
Study 34904689 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention for medical students
Number of subjects: 127
Study 34413118 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Number of subjects: 0
Study 34413118 — intervention group
Group type: COMPARATOR
Intervention: Native human insulin (HI)
Number of subjects: 0
Study 33253354 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (BACE inhibitor)
Number of subjects: 0
Study 33253354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33253354 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat
Number of subjects: 0
Study 33253354 — intervention group
Group type: COMPARATOR
Intervention: Verubecestat and Placebo
Number of subjects: 0
Study 35834528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose micronutrient-antioxidant supplement
Number of subjects: 171
Study 35834528 — intervention group
Group type: COMPARATOR
Intervention: RDA supplement
Number of subjects: 171
Study 34210274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic and protein supplementation
Number of subjects: 0
Study 34210274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) and protein supplementation
Number of subjects: 0
Study 34996047 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient clinical trial infrastructure
Number of subjects: 0
Study 34996047 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system resiliency framework
Number of subjects: 0
Study 33750879 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrate diet feeding pattern
Number of subjects: 12
Study 33750879 — intervention group
Group type: COMPARATOR
Intervention: Intensively reared group (control)
Number of subjects: 12
Study 35490229 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific dietary and behavioral counseling
Number of subjects: 0
Study 35490229 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 0
Study 32720121 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT (Neoadjuvant Chemotherapy)
Number of subjects: 21
Study 32720121 — intervention group
Group type: EXPERIMENTAL
Intervention: NACTRT (Neoadjuvant Chemoradiotherapy)
Number of subjects: 21
Study 32720121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NACT and NACTRT
Number of subjects: 21
Study 32720121 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant RT (Radiotherapy)
Number of subjects: 21
Study 32720121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal recurrence after RT (either neoadjuvant or adjuvant)
Number of subjects: 21
Study 35763437 — intervention group
Group type: EXPERIMENTAL
Intervention: SCGS with concurrent acne treatments
Number of subjects: 66
Study 35763437 — intervention group
Group type: COMPARATOR
Intervention: SCGS and Placebo
Number of subjects: 66
Study 32239958 — intervention group
Group type: EXPERIMENTAL
Intervention: Palladium/norbornene (Pd/NBE) catalysis under Catellani reaction conditions with lithium salts and olefins
Number of subjects: 0
Study 32239958 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic deuterium labeling and crossover experiments
Number of subjects: 0
Study 35217746 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene care administered every 24 hours
Number of subjects: 57
Study 35217746 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene care
Number of subjects: 57
Study 34645413 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneSHARE (website designed to increase family communication of genetic test results)
Number of subjects: 0
Study 34645413 — intervention group
Group type: EXPERIMENTAL
Intervention: My Gene Counsel's Living Lab Report (digital tool designed to improve understanding of genetic test results and next steps, including CRM guidelines)
Number of subjects: 0
Study 34645413 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 0
Study 34608929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (1, 5, 10, 15 mg)
Number of subjects: 259
Study 34608929 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 259
Study 34608929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 33370506 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Therapy (VT)
Number of subjects: 51
Study 33370506 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Electrical Stimulation (SES)
Number of subjects: 51
Study 35710241 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based virtual journal clubs
Number of subjects: 75
Study 35710241 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face journal clubs
Number of subjects: 75
Study 32577737 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-band group
Number of subjects: 43
Study 32577737 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical Ankle Platform System group
Number of subjects: 43
Study 32577737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (resistance‐band and Biomechanical Ankle Platform System)
Number of subjects: 43
Study 32577737 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 33608048 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg tianeptine
Number of subjects: 38
Study 33608048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32717713 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 100 and 200 mg/day
Number of subjects: 764
Study 32717713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 764
Study 35263517 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of standard first-line antituberculosis treatment
Number of subjects: 1204
Study 35263517 — intervention group
Group type: COMPARATOR
Intervention: 6 months of standard first-line antituberculosis treatment
Number of subjects: 1204
Study 35263517 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of treatment
Number of subjects: 1204
Study 35263517 — intervention group
Group type: COMPARATOR
Intervention: 6 months of treatment
Number of subjects: 1204
Study 35263517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1204
Study 36216945 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 304
Study 36216945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 34004483 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab (15 mg/kg intravenously once monthly)
Number of subjects: 2
Study 32690063 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN (Long-Lasting Insecticidal Nets)
Number of subjects: 36
Study 32690063 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide-treated LLIN (PBO Nets)
Number of subjects: 36
Study 32690063 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN + IRS (Indoor Residual Spraying)
Number of subjects: 36
Study 32690063 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO Nets + LSM (Larval Source Management)
Number of subjects: 36
Study 32690063 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN + IRS + LSM
Number of subjects: 36
Study 32690063 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO Nets + IRS
Number of subjects: 36
Study 36052613 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized wet suction
Number of subjects: 50
Study 36052613 — intervention group
Group type: COMPARATOR
Intervention: Dry suction
Number of subjects: 50
Study 36052613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 50
Study 34455435 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oil (high-dose, purified omega-3 fatty acids) mimicking REDUCE-IT
Number of subjects: 12546
Study 34455435 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oil (high-dose, purified omega-3 fatty acids) mimicking STRENGTH
Number of subjects: 12546
Study 34455435 — intervention group
Group type: COMPARATOR
Intervention: Comparator oil (mineral oil) mimicking REDUCE-IT
Number of subjects: 12546
Study 34455435 — intervention group
Group type: COMPARATOR
Intervention: Comparator oil (corn oil) mimicking STRENGTH
Number of subjects: 12546
Study 34455435 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oil vs. comparator oil mimicking REDUCE-IT
Number of subjects: 12546
Study 34455435 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oil vs. comparator oil mimicking STRENGTH
Number of subjects: 12546
Study 32931919 — intervention group
Group type: EXPERIMENTAL
Intervention: Coproduced, nurse-led intervention delivered with general practitioners
Number of subjects: 0
Study 32931919 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 32931919 — intervention group
Group type: EXPERIMENTAL
Intervention: Coproduced, nurse-led intervention
Number of subjects: 0
Study 32955081 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide plus nebulized interferon alpha 2a (IFN‐α‐2a)
Number of subjects: 50
Study 32955081 — intervention group
Group type: COMPARATOR
Intervention: Nebulized interferon alpha 2a (IFN‐α‐2a) alone
Number of subjects: 50
Study 32046750 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formula
Number of subjects: 180
Study 32046750 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 180
Study 32986470 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended early intervention (EI)
Number of subjects: 220
Study 32986470 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 220
Study 32748972 — intervention group
Group type: EXPERIMENTAL
Intervention: ToM training condition
Number of subjects: 210
Study 32748972 — intervention group
Group type: COMPARATOR
Intervention: no-ToM training condition
Number of subjects: 210
Study 32147182 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a for 3 months before IVF (group A, n = 200)
Number of subjects: 400
Study 32147182 — intervention group
Group type: COMPARATOR
Intervention: IVF without GnRH‐a (group B, n = 200)
Number of subjects: 400
Study 32147182 — intervention group
Group type: COMPARATOR
Intervention: Tubal factor infertility (n = 200)
Number of subjects: 400
Study 32147182 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a for 3 months before IVF (group A)
Number of subjects: 400
Study 32147182 — intervention group
Group type: COMPARATOR
Intervention: IVF without GnRH‐a (group B)
Number of subjects: 400
Study 36131603 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid
Number of subjects: 37
Study 34948633 — intervention group
Group type: EXPERIMENTAL
Intervention: breastmilk odor + routine care
Number of subjects: 120
Study 34948633 — intervention group
Group type: EXPERIMENTAL
Intervention: breastmilk odor + taste + routine care
Number of subjects: 120
Study 34948633 — intervention group
Group type: COMPARATOR
Intervention: routine care (gentle touch + verbal comfort)
Number of subjects: 120
Study 35170482 — intervention group
Group type: EXPERIMENTAL
Intervention: Various aspects of care variables (including satisfaction with explanations, overall satisfaction with provider, learning about their medical conditions and clinician's personal manner)
Number of subjects: 34
Study 35170482 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 34
Study 34656205 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ComB (12 sessions)
Number of subjects: 36
Study 34656205 — intervention group
Group type: COMPARATOR
Intervention: Minimal Attention Control (MAC)
Number of subjects: 36
Study 32204896 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals who declared to be donors (67.5%)
Number of subjects: 868
Study 32204896 — intervention group
Group type: EXPERIMENTAL
Intervention: All individuals surveyed (90% regardless of donation status)
Number of subjects: 868
Study 32746730 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment Video-feedback Intervention (AVI)
Number of subjects: 88
Study 32746730 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducative intervention (PI)
Number of subjects: 88
Study 32746730 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized comparison group (RS)
Number of subjects: 88
Study 32410697 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical management (rehabilitation)
Number of subjects: 320
Study 32410697 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (reconstruction)
Number of subjects: 320
Study 35725494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine continuous parasternal block at 7 ml/hour for 72 hours
Number of subjects: 45
Study 35725494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine continuous parasternal block
Number of subjects: 45
Study 35725494 — intervention group
Group type: COMPARATOR
Intervention: Saline continuous parasternal block
Number of subjects: 45
Study 35285173 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg
Number of subjects: 466
Study 35285173 — intervention group
Group type: COMPARATOR
Intervention: liraglutide 0.9 mg
Number of subjects: 466
Study 35613822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg plus bevacizumab 15 mg/kg every 3 weeks
Number of subjects: 38
Study 34652968 — intervention group
Group type: COMPARATOR
Intervention: Standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles
Number of subjects: 642
Study 34652968 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy with five cycles of vincristine, topotecan, and cyclophosphamide (VTC) within the 17 cycles (regimen B)
Number of subjects: 642
Study 34571210 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video about induction of labor
Number of subjects: 119
Study 35671133 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided Attention (DA) + Positive Memory Reframing (PMR)
Number of subjects: 41
Study 32634774 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational tool
Number of subjects: 305
Study 616896253 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 73
Study 616896253 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 73
Study 36088786 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking events with greater pre-drinking relationship harmony
Number of subjects: 249
Study 36088786 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking events with greater pre-drinking relationship discord
Number of subjects: 249
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: UNRWA clinics for physical and biochemical measurements
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of blood pressure and blood glucose
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with hypertension
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with cardiovascular diseases (CVDs)
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with rheumatic diseases
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed hypertension
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled diabetes
Number of subjects: 959
Study 34227954 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 959
Study 34606387 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-as-Context (SAC)
Number of subjects: 105
Study 34606387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal (CR)
Number of subjects: 105
Study 34606387 — intervention group
Group type: COMPARATOR
Intervention: Control (brochure reading)
Number of subjects: 105
Study 32747497 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion (0.006 μg/kg/min for 72 hours)
Number of subjects: 58
Study 32747497 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 58